Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes

Primary Care Diabetes

Volumn 8, Issue 3, 2014, Pages 265-270

  Hirata, Takumi ^a   Inukai, Kouichi ^b   Morimoto, Jiro ^c   Katayama, Shigehiro ^d   Ishida, Hitoshi ^b  

^a FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAITAMA SOCIAL INSURANCE HOSPITAL   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Concomitant drugs; Glycemic control; Sitagliptin; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; HEMOGLOBIN A1C; INSULIN SENSITIZING AGENT; MITIGLINIDE; SITAGLIPTIN; SULFONYLUREA; THIAZOLE DERIVATIVE; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; BODY MASS; CONFOUNDING VARIABLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; POLYPHARMACY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; EPIDEMIOLOGY; ETHNOLOGY; GLUCOSE BLOOD LEVEL; JAPAN; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; RISK; STATISTICAL MODEL; TIME;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GLYCOSIDE HYDROLASE INHIBITORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; JAPAN; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PYRAZINES; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84908356212     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2014.01.008     Document Type: Article

References (19)

1. P. Aschner, M.S. Kipnes, and J.K. Lunceford et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 29 2006 2632 2637 (Pubitemid 44912190)
2. K. Watanabe, K. Kobayashi, and M. Takemoto et al. Sitagliptin improves postprandial hyperglycemia by inhibiting glucagon secretion in Werner syndrome with diabetes Diabetes Care 36 2013 e119
3. E. Muscelli, A. Casolaro, and A. Gastaldelli et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes mellitus J. Clin. Endocrinol. Metab. 97 2012 2818 2826
4. G.V. Sangle, L.M. Lauffer, and A. Grieco et al. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue Endocrinology 153 2012 564 573
5. S.S. Engel, E. Round, and G.T. Golm et al. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies Diabetes Ther. 4 2013 119 145
6. D.T. Eurich, S. Simpson, and A. Senthilselvan et al. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study BMJ 346 2013 f2267
7. K. Gooβen, and S. Gräber Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis Diabetes Obes. Metab. 14 2012 1061 1072
8. H. Park, C. Park, and Y. Kim et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis Ann. Pharmacother. 46 2012 1453 1469
9. T. Nomiyama, Y. Akehi, and H. Takenoshita et al. Contributed factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes Diabetes Res. Clin. Pract. 95 2012 e87 e88
10. H. Maeda, A. Kubota, and Y. Tanaka et al. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes Diabetes Res. Clin. Pract. 95 2012 e20 e22
11. S.A. Kim, W.H. Shim, and E.H. Lee et al. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus Diabetes Metab. J. 35 2011 159 165
12. American Diabetes Association (ADA) Standards of medical care in diabetes - 2009 Diabetes Care 32 Suppl. 1 2009 S13 S61
13. American Association of Clinical Endocrinologist (AACE) Diabetes Mellitus Clinical Practice Guidelines Task Force AACE medical guidelines for clinical practice for the management of diabetes mellitus Endocr. Pract. 13 Suppl. 1 2007 1 68
14. D. Sato, Y. Sato, S. Masuda, and H. Kimura Impact of the sitagliptin alert on prescription of oral antihyperglycemic drugs in Japan Int. J. Clin. Pharm. 34 2012 917 924
15. Y.G. Kim, S. Hahn, and T.J. Oh et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis Diabetologia 56 2013 696 708
16. K. Esposito, P. Chiodini, and G. Bellastella et al. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78,945 patients Diabetes Obes. Metab. 14 2012 228 233
17. Y. Moritoh, K. Takeuchi, and M. Hazama Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice J. Pharmacol. Exp. Ther. 329 2009 669 676
18. T. Narita, Y. Katsuura, and T. Sato et al. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients Diabet. Med. 26 2009 187 188
19. M. Kishimoto, and M. Noda A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers Cardiovasc. Diabetol. 10 2011 115